CD274 and renal cell carcinoma: In patients, the therapeutic blockade of PD-L1 contrasts effectively different tumors, such as classic Hodgkin lymphoma (HL), melanoma (127), non–small cell lung cancer (NSCLC), small cell lung cancer (128), urothelial carcinoma, renal cell carcinoma (RCC) (129), gastric carcinomas, and hepatocellular carcinoma (130).